{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:17:11Z","timestamp":1790705831766,"version":"4.1.0"},"reference-count":65,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Preservatives continue to be in widespread use in ophthalmic medications due to the convenience they provide, regulatory requirements and the higher cost of alternatives. Benzalkonium chloride (BAK) remains the most commonly used preservative but there is a trend towards the use of preservative-free (PF)\u00a0drops for glaucoma, although at a higher price. An extensive body of literature explores BAK toxicity on ocular structures in animal and laboratory studies (in vitro and in vivo). Non-randomised controlled studies have provided some supporting evidence of its toxicity in patients, especially in those with pre-existing ocular surface disease (OSD) or on multiple medications. However, there have been very few randomised controlled trials  that compare the same medication with and without BAK preservative. Several of these trials have never been published in any peer reviewed journals. Notwithstanding, those that have been published, have not demonstrated any clear benefits of the BAK-free formulations. Short duration and exclusion of those with OSD are limitations of these studies. There is a lack of evidence of clinically significant harm from a small number of BAK preserved drops in patients without OSD. This means that generally more expensive PF glaucoma medications should only be recommended for those on poly pharmacy or those with OSD but are not necessarily required for all patients.<\/jats:p>","DOI":"10.1136\/bjophthalmol-2017-311544","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T16:27:33Z","timestamp":1530721653000},"page":"1497-1503","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":119,"title":["Preservatives in glaucoma\u00a0medication"],"prefix":"10.1136","volume":"102","clinical-trial-number":[{"clinical-trial-number":"nct00798759","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00690794","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00527592","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David W","family":"Steven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Alaghband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3897-1633","authenticated-orcid":false,"given":"Kin Sheng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,7,4]]},"reference":[{"key":"2020050713002809000_102.11.1497.1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/jop.2013.0174","article-title":"Benzalkonium chloride and glaucoma","volume":"30","author":"Rasmussen","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"2020050713002809000_102.11.1497.2","doi-asserted-by":"publisher","DOI":"10.1586\/17469899.4.1.59"},{"key":"2020050713002809000_102.11.1497.3","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1994.01090230060021"},{"key":"2020050713002809000_102.11.1497.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.03.001"},{"key":"2020050713002809000_102.11.1497.5","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32835c8aba"},{"key":"2020050713002809000_102.11.1497.6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.sjopt.2014.06.006","article-title":"Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives","volume":"28","author":"Tu","year":"2014","journal-title":"Saudi J Ophthalmol"},{"key":"2020050713002809000_102.11.1497.7","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0029-x"},{"key":"2020050713002809000_102.11.1497.8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/eye.2012.25","article-title":"Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?","volume":"26","author":"Lockington","year":"2012","journal-title":"Eye"},{"key":"2020050713002809000_102.11.1497.9","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2011.626909"},{"key":"2020050713002809000_102.11.1497.10","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.189449"},{"key":"2020050713002809000_102.11.1497.11","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0776"},{"key":"2020050713002809000_102.11.1497.12","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1067"},{"key":"2020050713002809000_102.11.1497.13","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-1331"},{"key":"2020050713002809000_102.11.1497.14","doi-asserted-by":"publisher","DOI":"10.1080\/02713680801971857"},{"key":"2020050713002809000_102.11.1497.15","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1994.01090230051020"},{"key":"2020050713002809000_102.11.1497.16","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-199811000-00001"},{"key":"2020050713002809000_102.11.1497.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.03.006"},{"key":"2020050713002809000_102.11.1497.18","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2992"},{"key":"2020050713002809000_102.11.1497.19","doi-asserted-by":"crossref","unstructured":"Khoh-Reiter S , Jessen BA . Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol 2009;9:5.doi:10.1186\/1471-2415-9-5","DOI":"10.1186\/1471-2415-9-5"},{"key":"2020050713002809000_102.11.1497.20","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4835(89)90071-7"},{"key":"2020050713002809000_102.11.1497.21","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1993.1160"},{"key":"2020050713002809000_102.11.1497.22","first-page":"141","article-title":"Epinephrine-induced toxicity of human trabecular cells in vitro","volume":"6","author":"Tripathi","year":"1989","journal-title":"Lens Eye Toxic Res"},{"key":"2020050713002809000_102.11.1497.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-003-0777-7"},{"key":"2020050713002809000_102.11.1497.24","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1007\/s00216-013-6811-7","article-title":"Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry","volume":"405","author":"Desbenoit","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"2020050713002809000_102.11.1497.25","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.6.835"},{"key":"2020050713002809000_102.11.1497.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.06.052"},{"key":"2020050713002809000_102.11.1497.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.10.050"},{"key":"2020050713002809000_102.11.1497.28","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0886-3350(03)00560-1","article-title":"ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy","volume":"29","author":"Miyake","year":"2003","journal-title":"J Cataract Refract Surg"},{"key":"2020050713002809000_102.11.1497.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1755-0"},{"key":"2020050713002809000_102.11.1497.30","doi-asserted-by":"publisher","DOI":"10.1159\/000055579"},{"key":"2020050713002809000_102.11.1497.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(92)31847-0"},{"key":"2020050713002809000_102.11.1497.32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"2020050713002809000_102.11.1497.33","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.4.418"},{"key":"2020050713002809000_102.11.1497.34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/OPTH.S28104","article-title":"Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma","volume":"6","author":"Janulevi\u010dien\u0117","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"2020050713002809000_102.11.1497.35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/IJG.0b013e318264cd68","article-title":"Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control","volume":"23","author":"Batra","year":"2014","journal-title":"J Glaucoma"},{"key":"2020050713002809000_102.11.1497.36","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.5.615"},{"key":"2020050713002809000_102.11.1497.37","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P268"},{"key":"2020050713002809000_102.11.1497.38","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302121"},{"key":"2020050713002809000_102.11.1497.39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/OPTH.S91402","article-title":"Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials","volume":"10","author":"Uusitalo","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"2020050713002809000_102.11.1497.40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/OPTH.S14113","article-title":"Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost","volume":"4","author":"Katz","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"2020050713002809000_102.11.1497.41","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00417-010-1397-7","article-title":"Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide\/timolol fixed combination (COSOPT\u2122) in patients with elevated intraocular pressure in a randomized clinical trial","volume":"248","author":"Shedden","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2020050713002809000_102.11.1497.42","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-303040"},{"key":"2020050713002809000_102.11.1497.43","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304064"},{"key":"2020050713002809000_102.11.1497.44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.17925\/EOR.2010.04.01.23","article-title":"Preservative-free treatment in glaucoma is a sensible and realistic aim for the future","volume":"04","author":"Hopes","year":"2010","journal-title":"European Ophthalmic Review"},{"key":"2020050713002809000_102.11.1497.45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1442-9071.2012.02823.x","article-title":"Patient satisfaction with topical ocular hypotensives","volume":"41","author":"Kerr","year":"2013","journal-title":"Clin Exp Ophthalmol"},{"key":"2020050713002809000_102.11.1497.46","first-page":"785","article-title":"Patient satisfaction with glaucoma therapy: reality or myth?","volume":"9","author":"Lemij","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"2020050713002809000_102.11.1497.47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","article-title":"Ocular surface disease and quality of life in patients with glaucoma","volume":"153","author":"Skalicky","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"2020050713002809000_102.11.1497.48","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850204"},{"key":"2020050713002809000_102.11.1497.49","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12131"},{"key":"2020050713002809000_102.11.1497.50","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8775"},{"key":"2020050713002809000_102.11.1497.51","first-page":"851","article-title":"Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro","volume":"18","author":"Clouzeau","year":"2012","journal-title":"Mol Vis"},{"key":"2020050713002809000_102.11.1497.52","first-page":"262","article-title":"Reversal of topical antiglaucoma medication effects on the conjunctiva","volume":"114","author":"Broadway","year":"1996","journal-title":"Ophthalmol"},{"key":"2020050713002809000_102.11.1497.53","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31825af67d"},{"key":"2020050713002809000_102.11.1497.54","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/jop.2014.0008","article-title":"Does the use of preoperative antiglaucoma medications influence trabeculectomy success?","volume":"30","author":"\u00d6zt\u00fcrker","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"2020050713002809000_102.11.1497.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.064"},{"key":"2020050713002809000_102.11.1497.56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2016.06.014","article-title":"Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa","volume":"788","author":"Trzeciecka","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"2020050713002809000_102.11.1497.57","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ceo.12163","article-title":"Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost","volume":"42","author":"Kucukevcilioglu","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"2020050713002809000_102.11.1497.58","doi-asserted-by":"crossref","unstructured":"Miki T , Naito T , Fujiwara M , et al . Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS One 2017;12:e0181550.doi:10.1371\/journal.pone.0181550","DOI":"10.1371\/journal.pone.0181550"},{"key":"2020050713002809000_102.11.1497.59","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1994.01090230060021"},{"key":"2020050713002809000_102.11.1497.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.038"},{"key":"2020050713002809000_102.11.1497.61","unstructured":"British National Formulary (BNF). 72 edn: BMJ Publishing Group."},{"key":"2020050713002809000_102.11.1497.62","doi-asserted-by":"crossref","first-page":"116","DOI":"10.17925\/EOR.2011.05.02.116","article-title":"Adverse effects, adherence and cost\u2013benefits in glaucoma treatment","volume":"05","author":"Denis","year":"2011","journal-title":"Euro Ophthal Rev"},{"key":"2020050713002809000_102.11.1497.63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5301\/ejo.5000001","article-title":"Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma","volume":"22","author":"Gandolfi","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"2020050713002809000_102.11.1497.64","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2015.04.041","article-title":"Polyquaternium-1-preserved travoprost 0.003% or benzalkonium chloride-preserved travoprost 0.004% for glaucoma and ocular hypertension","volume":"160","author":"Peace","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2020050713002809000_102.11.1497.65","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.18203\/2319-2003.ijbcp20173744","article-title":"Efficacy and safety of topical BAK-free travoprost 0.004% versus BAK-preserved travoprost 0.004% in the treatment of primary open angle glaucoma: a comparative study at a tertiary care hospital","volume":"6","author":"Jayanthi","year":"2017","journal-title":"Int J Basic Clin Pharmacol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-311544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:56:48Z","timestamp":1601110608000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-311544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,4]]},"references-count":65,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,10,22]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/bjophthalmol-2017-311544"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311544","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,4]]}}}